How would you decide on VRd vs DRd for initial management of transplant ineligible multiple myeloma?

Both VRd and DRd are reasonable induction regimens for newly diagnosed transplant ineligible patients. DRd has the most direct evidence, as there is a phase III study (MAIA, Facon et al., NEJM, 2019) comparing DRd to Rd with both arms including treatment until progression in a transplant ineligible population. However, even with the updated analysis presented at ASH 2019 (abstract 1875), there has not been a long-enough follow-up to determine the median PFS of DRd (with a median follow-up of 36.4 months thus far). The median PFS for VRd from the SWOG S0777 study was 43 months (Durie et al., Lancet 2017). The caveats here are that the triplet was not continued until progression and that this study primarily enrolled transplant-eligible patie...